Cryo Cell International vs Exagen
Exagen reported revenue of $67 million in fiscal 2025, 2.1 times Cryo Cell International's $32 million in fiscal 2025. Cryo Cell International's revenue fell 1.3% in its latest year, and Exagen's grew 19.6%. Cryo Cell International had an operating margin of 1.5%, against -21.1% at Exagen. Free cash flow was $5 million at Cryo Cell International and −$14 million at Exagen. Their fiscal years end in different months (November 30 and December 31), so the periods don't line up exactly.
Side by side
| Cryo Cell International | Exagen | |
|---|---|---|
| Latest fiscal year | FY2025, Nov 30, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $32M | $67M |
| Revenue growth | −1.3% | 19.6% |
| Revenue growth a year, last 5 years | 0.3% | 9.7% |
| Gross margin | 76.6% | 58.3% |
| Operating margin | 1.5% | −21.1% |
| Net margin | −7.7% | −30.0% |
| Free cash flow | $5M | −$14M |
| Free cash flow margin | 16.6% | −21.4% |
| Return on capital | — | −115.0% |
| Net debt to EBITDA | 3.5x | — |
| Dividends and buybacks | $3M | $0M |
| Change in diluted share count | −1.8% | 18.4% |
| Last close | $4.15 | $3.80 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $252,640 |
| Piotroski F-score | 6 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Cryo Cell InternationalExagen
Operating margin
Percent of revenue
Cryo Cell InternationalExagen
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Cryo Cell InternationalExagen
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Cryo Cell International and Exagen pages.